2Department of Immunology, Dr. Sadi Konuk Training and Research Hospital, İstanbul-Turkey
3Department of Hematology, Gaziantep University, Faculty of Medicine, Gaziantep-Turkey
4Department of Oncology, Dr. Sadi Konuk Training and Research Hospital, İstanbul-Turkey
5Department of Medical Genetics, Hitit University, Faculty of Medicine, Çorum-Turkey DOI : 10.5505/tjo.2020.2186 OBJECTIVE
An increasing number of epidemiological and molecular evidence proposes that inflammation is a significant factor in the etiology of cancers. Macrophage Migration Inhibitory Factor (MIF) encodes a lymphokine involved in cell-mediated immunity, immunoregulation, and inflammation. It has been reported that MIF is linked with a higher risk of several cancer types. In the present study, we investigated the association of MIF rs755622 variant with the risk of breast cancer (BC) and gastrointestinal cancer in a Turkish cohort.
METHODS
The present study included a total of 153 subjects, which consisted of 33 BC patients, 53 gastrointestinal
cancer patients and 67 healthy controls. Genomic DNA extracted from peripheral venous blood. The
rs755622 variant of the MIF gene was genotyped using polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method. The results were statistically analyzed by calculating the
odds ratios (OR) and 95% confidence intervals (CI) using the ?2 test.
RESULTS
There was a statistical difference between the BC patients and controls for the MIF rs755622 variant.
MIF rs755622 GG genotype and G allele were increased in BC patients compared to controls (p=0.016,
p=0.017, respectively). No significant difference was observed between gastrointestinal cancer patients
and controls for the MIF rs755622 variant (p>0.05).
CONCLUSION
Our results showed that the MIF rs755622 variant might play a potential role in BC physiopathology.